Submissions from 2022
Uncovering potential interventions for pancreatic cancer patients via mathematical modeling., Daniel Plaugher, Boris Aguilar, and David Murrugarra
Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide., YaoYao Pollock, Matthew R Smith, Fred Saad, Simon Chowdhury, Stéphane Oudard, Boris Hadaschik, David Olmos, Ji Youl Lee, Hiroji Uemura, Amitabha Bhaumik, Anil Londhe, Brendan Rooney, Sabine D Brookman-May, Peter De Porre, Suneel D Mundle, and Eric J Small
Adjuvant and Neoadjuvant Therapies in Cutaneous Melanoma., Jay Ponto and Richard Bryan Bell
The effect of race on treatment patterns and subsequent health-related quality of life outcomes in men undergoing treatment for localized prostate cancer., Natasza M Posielski, Santosh Shanmuga, On Ho, Jiji Jiang, Sally Elsamanoudi, Ryan Speir, Sean Stroup, John Musser, Alexander Ernest, Gregory T Chesnut, Timothy Tausch, John Paul Flores, and Christopher Porter
Epacadostat Plus Pembrolizumab and Chemotherapy for Advanced Solid Tumors: Results from the Phase I/II ECHO-207/KEYNOTE-723 Study., John D Powderly, Samuel J Klempner, Aung Naing, Johanna Bendell, Ignacio Garrido-Laguna, Daniel V T Catenacci, Matthew H Taylor, James J Lee, Fred Zheng, Feng Zhou, Xiaohua Gong, Hema Gowda, and Gregory L Beatty
CT209 / 9 - A first-in-human phase 1 trial of IO-108, an antagonist antibody targeting LILRB2 (ILT4), as monotherapy and in combination with pembrolizumab in adult patients with advanced relapsed or refractory solid tumors (NCT05054348), John Powderly, Matthew H Taylor, and See full list of authors in comments
Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial., Matthew A Powell, Virginia L Filiaci, Martee L Hensley, Helen Q Huang, Kathleen N Moore, Krishnansu S Tewari, Larry J Copeland, Angeles A Secord, David G Mutch, Alessandro Santin, David P Warshal, Nick M Spirtos, Paul A DiSilvestro, Olga B Ioffe, and David S Miller
AACR Project GENIE: 100,000 cases and beyond., Trevor J Pugh, Jonathan L Bell, Jeff P Bruce, Gary J Doherty, Matthew Galvin, Michelle F Green, Haley Hunter-Zinck, Priti Kumari, Michele L LeNoue-Newton, Marilyn M Li, James Lindsay, Tali Mazor, Andrea Ovalle, Stephen-John Sammut, Nikolaus Schultz, Thomas V Yu, Shawn M Sweeney, Brady Bernard, and Aacr Project Genie Consortium
Does Residual Invasive Disease in Wide Local Excision after Diagnosis with Partial Biopsy Technique Influence Survival in Melanoma? Matched-Pair Analysis of Multicenter Selective Lymphadenectomy Trial I and II., Judi Anne B Ramiscal, Stacey L Stern, Ana K Wilson, Patrick D Lorimer, Nathaniel A Lee, Melanie R Goldfarb, Leland J Foshag, and Trevan D Fischer
PTPRD and CNTNAP2 as markers of tumor aggressiveness in oligodendrogliomas., Kirsi J Rautajoki, Serafiina Jaatinen, Aliisa M Tiihonen, Matti Annala, Elisa M Vuorinen, Anni Kivinen, Minna J Rauhala, Kendra K Maass, Kristian W Pajtler, Olli Yli-Harja, Pauli Helén, Joonas Haapasalo, Hannu Haapasalo, Wei Zhang, and Matti Nykter
Efficacy of oral and topical antioxidants in the prevention and management of oral mucositis in head and neck cancer patients: a systematic review and meta-analyses., Afsheen Raza, Nelli Karimyan, Amber L Watters, Chitra P Emperumal, Kamal Al-Eryani, and Reyes Enciso
Follow the Data: It Is Time to Incentivize the Use of Drug-Eluting Stents and Balloons., Mahmood K Razavi
Response to aPD-1 + aLAG-3 checkpoint blockade is associated with Treg functional reprogramming and instability, William Redmond
Multimodal single-cell analysis of human TILs across multiple tumor types reveals heterogeneity and potential opportunities for personalized immunotherapy, William L. Redmond
Novel mechanisms to augment the efficacy of cancer immunotherapy, William L. Redmond
Multimodal single-cell analysis of human tumor infiltrating immune cells across multiple tumor types reveals heterogeneity and potential opportunities for personalized immunotherapeutic strategies., William L. Redmond and See full list of authors in comments
Splenic vein aneurysm: Case report of an exceedingly rare condition, Dave Riesberg
Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8, Annah S Rolig, Daniel Rose, Grace Helen McGee, Werner Rubas, Saul Kivimäe, and William L. Redmond
Response to anti-PD-1 and anti-LAG-3 immune checkpoint blockade is associated with induction of pro-inflammatory Tregs., AS Rolig, William L. Redmond, and See full list of authors in comments
Gene-gene interaction of AhRwith and within the Wntcascade affects susceptibility to lung cancer., Albert Rosenberger, Nils Muttray, Rayjean J Hung, David C Christiani, Neil E Caporaso, Geoffrey Liu, Stig E Bojesen, Loic Le Marchand, Demetrios Albanes, Melinda C Aldrich, Adonina Tardon, Guillermo Fernández-Tardón, Gad Rennert, John K Field, Michael P A Davies, Triantafillos Liloglou, Lambertus A Kiemeney, Philip Lazarus, Bernadette Wendel, Aage Haugen, Shanbeh Zienolddiny, Stephen Lam, Matthew B Schabath, Angeline S Andrew, Eric J Duell, Susanne M Arnold, Gary E Goodman, Chu Chen, Jennifer A Doherty, Fiona Taylor, Angela Cox, Penella J Woll, Angela Risch, Thomas R Muley, Mikael Johansson, Paul Brennan, Maria Teresa Landi, Sanjay S Shete, Christopher I Amos, and Heike Bickeböller
A Phase III, Multicenter, Randomized Controlled Trial Investigating 1-cm Versus 2-cm Surgical Excision Margins for Stage II Primary Cutaneous Melanoma (MelMarT-II)., Alexander J Rossi, Emily A Verbus, Mark Faries, Marc Moncrieff, Michael Henderson, Jonathan M Hernandez, and Michael C Lowe
Uterine Sarcomas: How to Navigate an Ever-Growing List of Subtypes., Molly Roy, Fernanda Musa, Sarah E Taylor, and Marilyn Huang
"Oncologic Safety of Staged Pre-Pectoral Implant Reconstruction Following Nipple-Sparing Mastectomy: a Mean 9-Year Follow-Up.", Arthur H Salibian and Jay K Harness
Novel Combinatorial Approaches with LAG-3, Rachel Sanborn
Targeting OX-40 and LAG-3 to Overcome T-cell Exhaustion, Rachel Sanborn
Vaccines and emerging immunotherapy approaches for NSCLC, Rachel Sanborn
Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors., Rachel E Sanborn, Michael J Pishvaian, Margaret K Callahan, Amy Weise, Branimir I Sikic, Osama Rahma, Daniel C Cho, Naiyer A Rizvi, Mario Sznol, Jose Lutzky, Julie E Bauman, Rhonda L Bitting, Alexander Starodub, Antonio Jimeno, David A Reardon, Thomas Kaley, Fabio Iwamoto, Joachim M Baehring, Deepa S Subramaniam, Jeanny B Aragon-Ching, Thomas R Hawthorne, Tracey Rawls, Michael Yellin, and Tibor Keler
Beyond Checkpoint Inhibitors: Enhancing Antitumor Immune Response in Lung Cancer., Rachel E Sanborn, Famke L Schneiders, Suresh Senan, and Shirish M Gadgeel
Results from a phase 1 study of CDX-1140, a fully human anti-CD40 agonist monoclonal antibody (mAb), in combination with pembrolizumab, Rachel E. Sanborn and See all authors in comments
Beyond Checkpoint Inhibitors: Enhancing Antitumor Immune Response in Lung Cancer, Rachel E Sanborn and See full list of authors in comments
Disparities in the impact of the AJCC 8th edition staging system on differentiated thyroid cancer outcomes., Juan A Santamaria-Barria, Amanda N Graff-Baker, Shu-Ching Chang, Adam Khader, Anthony J Scholer, Mary Garland-Kledzik, and Melanie Goldfarb
Analytic pipelines to assess the relationship between immune response and germline genetics in human tumors., Rosalyn W Sayaman, Mohamad Saad, Carolina Heimann, Donglei Hu, Khalid Kunji, Jessica Roelands, Denise M Wolf, Scott Huntsman, Michele Ceccarelli, Vésteinn Thorsson, Elad Ziv, and Davide Bedognetti
Accounting for EGFR Mutations in Epidemiologic Analyses of Non-Small Cell Lung Cancers: Examples Based on the International Lung Cancer Consortium Data., Sabine Schmid, Mei Jiang, M Catherine Brown, Aline Fares, Miguel Garcia, Joelle Soriano, Mei Dong, Sera Thomas, Takashi Kohno, Leticia Ferro Leal, Nancy Diao, Juntao Xie, Zhichao Wang, David Zaridze, Ivana Holcatova, Jolanta Lissowska, Beata Świątkowska, Dana Mates, Milan Savic, Angela S Wenzlaff, Curtis C Harris, Neil E Caporaso, Hongxia Ma, Guillermo Fernandez-Tardon, Matthew J Barnett, Gary E Goodman, Michael P A Davies, Mónica Pérez-Ríos, Fiona Taylor, Eric J Duell, Ben Schoettker, Hermann Brenner, Angeline Andrew, Angela Cox, Alberto Ruano-Ravina, John K Field, Loic Le Marchand, Ying Wang, Chu Chen, Adonina Tardon, Sanjay Shete, Matthew B Schabath, Hongbing Shen, Maria Teresa Landi, Brid M Ryan, Ann G Schwartz, Lihong Qi, Lori C Sakoda, Paul Brennan, Ping Yang, Jie Zhang, David C Christiani, Rui Manuel Reis, Kouya Shiraishi, Rayjean J Hung, Wei Xu, and Geoffrey Liu
Validating biologic age in selecting elderly patients with pancreatic cancer for surgical resection., Anthony J Scholer, Rebecca Marcus, Mary Garland-Kledzik, Shu-Ching Chang, Adam Khader, Juan Santamaria-Barria, Zeljka Jutric, Ronald Wolf, and Melanie Goldfarb
Detection of perillyl alcohol and its metabolite perillic acid in postsurgical glioblastoma tissue after intranasal administration of NEO100: illustrative case., Axel H Schönthal, Steve Swenson, Phillip A Bonney, Naveed Wagle, Vincent F Simmon, Anna J Mathew, Kyle M Hurth, and Thomas C Chen
A Phase II Study Investigating Cabozantinib in Patients with Refractory Metastatic Colorectal Cancer (AGICC 17CRC01)., Aaron J Scott, Atrayee Basu Mallick, Efrat Dotan, Steven J Cohen, Philip J Gold, Howard S Hochster, Somasundaram Subramaniam, Afsaneh Barzi, George S Watts, Patrick J Blatchford, and Wells A Messersmith
The diverse landscape of dermatologic toxicities of non-immune checkpoint inhibitor monoclonal antibody-based cancer therapy., Riyad N H Seervai, Sarah K Friske, Emily Y Chu, Rhea Phillips, Kelly C Nelson, Auris Huen, Woo Cheal Cho, Phyu P Aung, Carlos A Torres-Cabala, Victor G Prieto, and Jonathan L Curry
Mechanisms of dermatologic toxicities to immune checkpoint inhibitor cancer therapies., Riyad N H Seervai, Avilasha Sinha, and Rajan P Kulkarni
Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study., Alison Sehgal, Daanish Hoda, Peter A Riedell, Nilanjan Ghosh, Mehdi Hamadani, Gerhard C Hildebrandt, John E Godwin, Patrick M Reagan, Nina Wagner-Johnston, James Essell, Rajneesh Nath, Scott R Solomon, Rebecca Champion, Edward Licitra, Suzanne Fanning, Neel Gupta, Ronald Dubowy, Aleco D'Andrea, Lei Wang, Ken Ogasawara, Jerill Thorpe, and Leo I Gordon
Glioblastoma Embryonic-like Stem Cells Exhibit Immune-Evasive Phenotype., Borja Sesé, Sandra Íñiguez-Muñoz, Miquel Ensenyat-Mendez, Pere Llinàs-Arias, Guillem Ramis, Javier I Orozco, Silvia Fernández de Mattos, Priam Villalonga, and Diego M Marzese
The impact of mentoring on early career faculty: Assessment of a virtual mentoring program., Akanksha Sharma, Heather Leeper, Soo Bang, Donna Molaie, and Alyx B. Porter
Advances in the Diagnosis and Treatment of Leptomeningeal Disease., Akanksha Sharma, Justin T Low, and Priya Kumthekar
Comparison of perioperative outcomes following transperitoneal versus retroperitoneal robot-assisted partial nephrectomy: a propensity-matched analysis of VCQI database., Gopal Sharma, Milap Shah, Puneet Ahluwalia, Prokar Dasgupta, Benjamin J Challacombe, Mahendra Bhandari, Rajesh Ahlawat, Sudhir Rawal, Nicolo M Buffi, Ananthkrishnan Sivaraman, James R Porter, Craig Rogers, Alexandre Mottrie, Ronney Abaza, Khoon Ho Rha, Daniel Moon, Thyavihally B Yuvaraja, Dipen J Parekh, Umberto Capitanio, Kris K Maes, Francesco Porpiglia, Levent Turkeri, and Gagan Gautam
772 A phase 1/2 dose escalation/expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of E-602, a bi-sialidase fusion protein, in advanced cancer (GLIMMER-01), Manish Sharma, Brendan Curti, and See all authors in comments
Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia., Jeff P Sharman, Miklos Egyed, Wojciech Jurczak, Alan Skarbnik, John M Pagel, Ian W Flinn, Manali Kamdar, Talha Munir, Renata Walewska, Gillian Corbett, Laura Maria Fogliatto, Yair Herishanu, Versha Banerji, Steven Coutre, George Follows, Patricia Walker, Karin Karlsson, Paolo Ghia, Ann Janssens, Florence Cymbalista, Jennifer A Woyach, Emmanuelle Ferrant, William G Wierda, Veerendra Munugalavadla, Ting Yu, Min Hui Wang, and John C Byrd
Immunotherapy in head and neck squamous cell carcinoma: a narrative review., Shay Sharon and R Bryan Bell
The immune landscape of solid pediatric tumors., Shimaa Sherif, Jessica Roelands, William Mifsud, Eiman I Ahmed, Christophe M Raynaud, Darawan Rinchai, Abbirami Sathappan, Ata Maaz, Ayman Saleh, Erdener Ozer, Khalid A Fakhro, Borbala Mifsud, Vésteinn Thorsson, Davide Bedognetti, and Wouter R L Hendrickx
Effect of 3-Dimensional, Virtual Reality Models for Surgical Planning of Robotic Prostatectomy on Trifecta Outcomes: A Randomized Clinical Trial., Joseph D Shirk, Robert Reiter, Eric M Wallen, Ray Pak, Thomas Ahlering, Ketan K Badani, and James R Porter
Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS)., Kohei Shitara, Toshihiko Doi, Hisashi Hosaka, Peter Thuss-Patience, Armando Santoro, Federico Longo, Ozgur Ozyilkan, Irfan Cicin, David J Park, Aziz Zaanan, Carles Pericay, Mustafa Özgüroğlu, Maria Alsina, Lukas Makris, Karim A Benhadji, and David H Ilson
Abstract A27: Impact of a validated composite comorbidity score on outcomes in patients treated with CAR T-cell therapy for diffuse large B cell lymphoma (DLBCL): A multicenter real-world evidence (RWE) study, Geoffrey Shouse, Neil Bailey, Krish Patel, and See all authors in comments
Impact of a Validated Composite Comorbidity Score on Outcomes in Patients Treated with CAR T-Cell Therapy for Diffuse Large B Cell Lymphoma (DLBCL): A Multicenter Real-World Evidence (RWE) Study, Geoffrey Shouse, Neil Bailey, Krish Patel, and See all authors in comments
Amivantamab and lazertinib in patients with EGFR-mutant non–small cell lung (NSCLC) after progression on osimertinib and platinum-based chemotherapy: Updated results from CHRYSALIS-2., Catherine A. Shu, Rachel E Sanborn, and See full list of authors in comments
A phase 1b single-arm trial of intratumoral oncolytic virus V937 in combination with pembrolizumab in patients with advanced melanoma: results from the CAPRA study., Ann W Silk, Steven O'Day, Howard L Kaufman, Jennifer Bryan, Jacqueline T Norrell, Casey Imbergamo, Daniella Portal, Edwin Zambrano-Acosta, Marisa Palmeri, Seymour Fein, Cai Wu, Leslie Guerreiro, Daniel Medina, Praveen K Bommareddy, Andrew Zloza, Bernard A Fox, Carmen Ballesteros-Merino, Yixin Ren, Darren Shafren, Mark Grose, Joshua A Vieth, and Janice M Mehnert
ASO Visual Abstract: Recurrence and Survival Rates for 1400 Early Breast Tumors Treated with Intraoperative Radiation Therapy (IORT)., Melvin J Silverstein, Melinda Epstein, Peter Chen, Kevin Lin, Sadia Khan, Lincoln Snyder, Colleen Coleman, Lisa Guerra, Farideh Dehkordi-Vakil, and Brian Kim
Psychometric Characteristics and Validity of the PROMIS Cancer Function Brief 3D Profile, Sean R. Smith, Mary Vargo, David S Zucker, Samman Shahpar, Lynn Gerber, Maryanne Henderson, Gina Jay, Minji Lee, and Andrea Cheville
Psychometric Characteristics and Validity of the PROMIS Cancer Function Brief 3D Profile, Sean R. Smith, Mary Vargo, David S Zucker, Samman Shahpar, Lynn Gerber, Maryanne Henderson, Gina Jay, Minji Lee, and Andrea Cheville
Responsiveness and interpretation of the PROMIS Cancer Function Brief 3D Profile., Sean R Smith, Mary Vargo, David S Zucker, Samman Shahpar, Lynn H Gerber, Maryanne Henderson, Gina Jay, and Andrea L Cheville
Contemporary, national patterns of surgery after preoperative therapy for stage II/III rectal adenocarcinoma., Celine Soriano, Henry T Bahnson, Jennifer A Kaplan, Bruce Lin, Ravi Moonka, Huong T Pham, Hagen F Kennecke, and Vlad Simianu
Clinical Oncology Nurse Best Practices: Palliative Care and End-of-Life Conversations., Kellie Spine, Anne Skwira-Brown, Deanna Schlifke, and Ellen Carr
Exploring approaches for predictive cancer patient digital twins: Opportunities for collaboration and innovation., Eric A Stahlberg, Mohamed Abdel-Rahman, Boris Aguilar, Alireza Asadpoure, Robert A Beckman, Lynn L Borkon, Jeffrey N Bryan, Colleen M Cebulla, Young Hwan Chang, Ansu Chatterjee, Jun Deng, Sepideh Dolatshahi, Olivier Gevaert, Emily J Greenspan, Wenrui Hao, Tina Hernandez-Boussard, Pamela R Jackson, Marieke Kuijjer, Adrian Lee, Paul Macklin, Subha Madhavan, Matthew D McCoy, Navid Mohammad Mirzaei, Talayeh Razzaghi, Heber L Rocha, Leili Shahriyari, Ilya Shmulevich, Daniel G Stover, Yi Sun, Tanveer Syeda-Mahmood, Jinhua Wang, Qi Wang, and Ioannis Zervantonakis
Severe breakthrough COVID-19 with a heavily mutated variant in a multiple myeloma patient 10 weeks after vaccination., Samuel D Stampfer, Marissa-Skye Goldwater, Sean Bujarski, Bernard Regidor, Wenjuan Zhang, Aaron J Feinstein, Regina Swift, Shahrooz Eshaghian, Eric Vail, and James R Berenson
Systemic therapy strategies in triple negative breast cancer, S Stanton
549 Booster vaccination of a HER2 helper T-cell vaccine increased HER2 immunity in metastatic HER2 positive breast cancer., Sasha Stanton, Jennifer Childs, Doreen Higgins, Angela Kask, Yi Yang, and Mary Disis
Phase I trial of the safety and immunogenicity of a tri-antigen vaccine targeting HER2, IGFBP-2, and IGF-IR in patients with non-metastatic breast cancer, Sasha E. Stanton and See all authors in comments
Neoadjuvant survivin-targeted immunotherapy maveropepimut-S (MVP-S) to increase Th1 immune response in Ki67-high hormone receptor-positive (HR+) early-stage breast cancer (ESBC)., Sasha Stanton, Lisa Diana MacDonald, Staci Mellinger, Nikki Moxon, Tracy L. Kelly, Heather Ann Hirsch, Stephan Fiset, Kristina H Young, and David B Page
646 Neoadjuvant immunotherapy combining maveropepimut-S (MVP-S) with letrozole decreases Ki67 and increases Th1 immune response in hormone receptor positive (HR+) early-stage breast cancer (ESBC), Sasha Stanton, David Page, Kristina Young, and See all authors in comments
Abstract PR007: Candidate antigens for a ductal carcinoma in situ vaccine, essential for breast cancer cell survival across multiple subtypes, are immunogenic in DCIS and IBC, Sasha Stanton, Jason Schlumbohm, and Mary L. Disis
Neoadjuvant survivin-targeted immunotherapy maveropepimut-S (MVP-S) to increase Th1 immune response in Ki67-high hormone receptor-positive (HR+) early-stage breast cancer (ESBC), Sasha Stanton and See all authors in comments
Phase I trial of the safety and immunogenicity of a tri-antigen vaccine targeting HER2, IGFBP-2, and IGF-IR in patients with non-metastatic breast cancer, Sasha Stanton and See all authors in comments
3380 / 8 - Seven autoantibody panel, validated in two independent patient serum collections, can detect women with DCIS and invasive breast cancer, Sasha Stanton and See full list of authors in comments
Neoadjuvant survivin-targeted immunotherapy maveropepimut-S (MVP-S) to increase Th1 immune response in Ki67-high hormone receptor-positive (HR+) early-stage breast cancer (ESBC)., Sasha Stanton, Kristina H Young, David B Page, and See all authors in comments
Immunology 101, SE Stanton
647 Phase I studies of AgenT-797, a novel allogeneic invariant natural killer T (iNKT) cell therapy, for the treatment of patients with solid tumors or multiple myeloma, Don Stevens, Rachel Sanborn, and See all authors in comments
Risk factors for reduced function in women with a history of breast cancer., Nicholas Stoyles, Andrea Cheville, David S Zucker, Blair Richards, Mary Vargo, Lynn Gerber, Samman Shahpar, Maryanne Henderson, Gina Jay, and Sean R Smith
Malignant Pilomatricoma of the Lower Extremity: A Difficult and Rare Diagnosis., Chaitra Subramanyam, Paige Dyrek, Xu Yao, and Martin H Kay
Blockade of interleukin 10 potentiates antitumour immune function in human colorectal cancer liver metastases., Kevin M Sullivan, Xiuyun Jiang, Prajna Guha, Christopher Lausted, Jason A Carter, Cynthia Hsu, Kevin P Labadie, Karan Kohli, Heidi L Kenerson, Sara K Daniel, Xiaowei Yan, Changting Meng, Arezou Abbasi, Marina Chan, Y David Seo, James O Park, Ian Nicholas Crispe, Raymond S Yeung, Teresa S Kim, Taranjit S Gujral, Qiang Tian, Steven C Katz, and Venu G Pillarisetty
Anomaly Detection Framework for Wearables Data: A Perspective Review on Data Concepts, Data Analysis Algorithms and Prospects., Jithin S Sunny, C Pawan K Patro, Khushi Karnani, Sandeep C Pingle, Feng Lin, Misa Anekoji, Lawrence D Jones, Santosh Kesari, and Shashaanka Ashili
Multiple Early Factors Anticipate Post-Acute COVID-19 Sequelae, Yapeng Su, Dan Yuan, Daniel G. Chen, Rachel H. Ng, Kai Wang, Jongchan Choi, Sarah Li, Sunga Hong, Rongyu Zhang, Jingyi Xie, Sergey A Kornilov, Kelsey Scherler, Ana Jimena Pavlovitch-Bedzyk, Shen Dong, Christopher Lausted, Inyoul Lee, Shannon Fallen, Chengzhen L Dai, Priyanka Baloni, Brett Smith, Venkata R Duvvuri, Kristin G. Anderson, Jing Li, Fan Yang, Caroline J. Duncombe, Denise J. McCulloch, Clifford Rostomily, Pamela Troisch, Jing Zhou, Sean Mackay, Quinn DeGottardi, Damon H. May, Ruth Taniguchi, Rachel M. Gittelman, Mark Klinger, Thomas M. Snyder, Ryan Roper, Gladys Wojciechowska, Kim Murray, Rick Edmark, Simon Evans, Lesley Jones, Yong Zhou, Lee Rowen, Rachel Liu, William Chour, Heather A Algren, William R Berrington, Julie A Wallick, Rebecca A. Cochran, Mary Micikas, ISB-Swedish COVID19 Biobanking Unit, Terri Wrin, Christos J. Petropoulos, Hunter R. Cole, Trevan D Fischer, Wei Wei, Dave SB Hoon, Nathan D Price, Naeha Subramanian, Joshua A. Hill, Jennifer J Hadlock, Andrew T. Magis, Antoni Ribas, Lewis L. Lanier, Scott D. Boyd, Jeffrey A. Bluestone, Helen Chu, Leroy Hood, Raphael Gottardo, Philip D. Greenberg, Mark M. Davis, Jason D Goldman, and James R. Heath
Health-related quality-of-life analyses from a multicenter, randomized, double-blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 mg/day., Matthew H. Taylor, Sophie Leboulleux, Yury Panaseykin, Bhavana Konda, Christelle de La Fouchardiere, Brett G M Hughes, Andrew G Gianoukakis, Young Joo Park, Ilia Romanov, Monika K Krzyzanowska, Diana Garbinsky, Bintu Sherif, Jie Janice Pan, Terri A Binder, Nicholas Sauter, Ran Xie, and Marcia S Brose
IO in Thyroid Cancer, Michael Taylor
SL-Cloud: A Cloud-based resource to support synthetic lethal interaction discovery., Bahar Tercan, Guangrong Qin, Taek-Kyun Kim, Boris Aguilar, John Phan, William Longabaugh, David Pot, Christopher J Kemp, Nyasha Chambwe, and Ilya Shmulevich
Survival with Cemiplimab in Recurrent Cervical Cancer., Krishnansu S Tewari, Bradley J Monk, Ignace Vergote, Austin Miller, Andreia C de Melo, Hee-Seung Kim, Yong Man Kim, Alla Lisyanskaya, Vanessa Samouëlian, Domenica Lorusso, Fernanda Damian, Chih-Long Chang, Evgeniy A Gotovkin, Shunji Takahashi, Daniella Ramone, Joanna Pikiel, Beata Maćkowiak-Matejczyk, Eva M Guerra Alía, Nicoletta Colombo, Yulia Makarova, Danny Rischin, Stephanie Lheureux, Kosei Hasegawa, Keiichi Fujiwara, Jingjin Li, Shaheda Jamil, Vladimir Jankovic, Chieh-I Chen, Frank Seebach, David M Weinreich, George D Yancopoulos, Israel Lowy, Melissa Mathias, Matthew G Fury, Ana Oaknin, and Investigators for GOG Protocol 3016 and ENGOT Protocol En-Cx9
TP022/#1424 A phase I/II study evaluating intraperitoneal GEN-1 in combination with neoadjuvant chemotherapy in patients newly diagnosed with advanced epithelial ovarian cancer, Premal Thaker, Melanie Bergman, and See all authors in comments
Critical appraisal of minimally invasive keyhole surgery for intracranial meningioma in a large case series., Jai Deep Thakur, Regin Jay Mallari, Alex Corlin, Samantha Yawitz, Amy Eisenberg, John Rhee, Walavan Sivakumar, Howard Krauss, Neil A Martin, Chester Griffiths, Garni Barkhoudarian, and Daniel F Kelly
409 Manufacturing of a clinical scale CD8 TIL product, AGX148, with and without gene silencing of PD-1 using self-delivering RNAi INTASYLTM PH-762, Colin Thalhofer, Tarsem Moudgil, Bernard A Fox, Nelson Sanjuan Silva, Eric Tran, and See all authors in comments
Enriching for tumor-reactive CD8 TIL (AGX148) leads to effective tumor clearance in a patient-derived xenograft model, C Thalhofer, Andrew D Weinberg, and See full list of authors in comments
Association of PD-L1 expression, tumor mutational burden and immunotherapy with venous thrombosis in patients with solid organ malignancies., Rajat Thawani, Thomas Kartika, Benjamin Elstrott, Elizabeth Batiuk, Derrick L Tao, Sonia Gowda, Lilian Chen, Corinne Lavasseur, Nattapron Tun, Nicholas F Taflin, and Joseph Shatzel
Outcomes of Therapies and Resistance Mutations Following Non-Covalent Bruton's Tyrosine Kinase Inhibitor Treatment for Patients with Chronic Lymphocytic Leukemia and Richter Transformation, Meghan C. Thompson, Krish Patel, Neil Bailey, and See all authors in comments
Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer., James T Topham, Chris J O'Callaghan, Harriet Feilotter, Hagen F Kennecke, Young S Lee, Weimin Li, Kimberly C Banks, Katie Quinn, Daniel J Renouf, Derek J Jonker, Dongsheng Tu, Eric X Chen, and Jonathan M Loree
Cell transfer therapy targeting mutated neoantigens in epithelial cancer, E Tran
Targeting mutant KRAS with adoptive T-cell therapy, E Tran
Targeting mutant KRAS with TCR-gene therapy, E Tran
TCR-gene therapy targeting mutant KRAS, E Tran
Targeting mutant KRAS with TCR-gene therapy, Eric Tran
TILs Update, Eric Tran
Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer. Reply., Eric Tran, Walter Urba, and Rom Leidner
